Page last updated: 2024-12-11
5'-oleoyl cytarabine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
elaidic acid-cytarabine: a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6438895 |
| CHEMBL ID | 2105665 |
| CHEBI ID | 177700 |
| SCHEMBL ID | 15140172 |
| MeSH ID | M0137506 |
Synonyms (42)
| Synonym |
|---|
| 5'-oleoyl cytarabine |
| 101235-34-1 |
| CHEBI:177700 |
| [(2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (e)-octadec-9-enoate |
| elaidic acid-cytarabine |
| p-4055 |
| cp-4055 |
| elacyt |
| elacytarabine |
| ta7wjg93ar , |
| elacytarabine [usan:inn] |
| cp 4055 |
| 2(1h)-pyrimidinone, 4-amino-1-(5-o-((9e)-1-oxo-9-octadecenyl)-beta-d-arabinofuranosyl)- |
| unii-ta7wjg93ar |
| elacytarabine (usan/inn) |
| D09712 |
| 188181-42-2 |
| CHEMBL2105665 |
| 2(1h)-pyrimidinone, 4-amino-1-(5-o-(1-oxo-9-octadecenyl)-beta-d-arabinofuranosyl)-, (z)- |
| cp4055 |
| 5'-oleyl-ara-c |
| 5'-oleoyl cytosine arabinoside |
| DB05494 |
| elacytarabine [usan] |
| 5'-o-(trans-9''-octadecenoyl)-1-ss-d-arabinofuranosyl cytosine |
| 2(1h)-pyrimidinone, 4-amino-1-(5-o-((9e)-1-oxo-9-octadecen-1-yl)-.beta.-d-arabinofuranosyl)- |
| elacytarabine [inn] |
| 4-amino-1-(5-o-((9e)-octadec-9-enoyl)-.beta.-d-arabinofuranosyl)pyrimidin-2(1h)-one |
| elacytarabine [who-dd] |
| 2(1h)-pyrimidinone, 4-amino-1-(5-o-((9e)-1-oxo-9-octadecenyl)-.beta.-d-arabinofuranosyl)- |
| SCHEMBL15140172 |
| ((2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl (e)-octadec-9-enoate |
| CS-0003647 |
| HY-14941 |
| EX-A3127 |
| 5'-o-(elaidoyl) 1-beta-d-arabinofuranosylcytosine |
| Q27289866 |
| (e)-((2r,3s,4s,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl octadec-9-enoate. |
| 5/'-oleoyl cytarabine |
| DTXSID601031218 |
| cytarabine-5'-elaidate |
| AKOS040741571 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Elacytarabine is clinically active in relapsed/refractory AML: overall response rate (CR + CRi) was 44% (16/36 with 7 non-evaluable patients) and adverse events were manageable." | ( Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Bergua, JM; Chevassut, T; Duarte, R; Gianella-Borradori, A; Hals, PA; Jacobsen, TF; Johansen, M; Knapper, S; Rasch, W; Salamero, O; Smith, M, 2014) | 0.4 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5'-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts." | ( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013) | 0.39 |
| "The antitumor activity of elacytarabine, was tested at the maximal tolerable dose (MTD; 50 mg/kg) and half MTD (25 mg/kg), alone and in combination with the antibodies bevacizumab (5 mg/kg), cetuximab (20 mg/kg) and trastuzumab (4 mg/kg) in two human non-small cell lung cancer xenografts." | ( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013) | 0.39 |
| " In the elacytarabine-, bevacizumab- and trastuzumab-insensitive MAKSAX xenograft, the combination of either bevacizumab or trastuzumab with elacytarabine at the MTD or half MTD resulted in intermediate activity, suggesting a beneficial effect of the combinations, whereas for cetuximab, the effect was enhanced when combined with elacytarabine given at the MTD, but not half-MTD." | ( Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts. Bruheim, S; Fodstad, O; Mælandsmo, GM; Sandvold, ML, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| pyrimidine nucleoside | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.90) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (33.33%) | 5.53% |
| Reviews | 3 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (52.38%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||